ReviewFrontiers in medicine2020
Role of Radiofrequency Ablation in the Management of Unresectable Pancreatic Cancer.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Role of Endoscopic Ultrasonography in Management of Pancreaticobiliary Cancers: Recent Trends and Advances.Cancers · 2026Review
- Spatial Porosity as a Diagnostic Predictor of Conductivity Collapse in Patient-Specific Radiofrequency Ablation of Liver Tumors.Diagnostics (Basel, Switzerland) · 2026Article
- Advances in radiofrequency ablation for pancreatic cancer.World journal of gastrointestinal oncology · 2026Review
- Non-Invasive Pancreas Ablation Using Histotripsy: Pre-clinical Safety Study in an In Vivo Porcine Model.Ultrasound in medicine & biology · 2026Article
- Safety and Efficacy of Radiofrequency Ablation in Management of Various Pancreatic Neoplasms.Journal of clinical medicine · 2025Article
- Anti-PD-1 synergizes with RFA to suppress abscopal tumors and induce durable memory against recurrence in HCC.Liver research (Beijing, China) · 2025Article
- Review
- Role of endoscopic ultrasound in the diagnosis and local ablative therapy of pancreatic neuroendocrine tumors.The Korean journal of internal medicine · 2025Review
- Review
- EUS-Guided Radiofrequency Ablation Therapy for Pancreatic Neoplasia.Diagnostics (Basel, Switzerland) · 2024Review
- Evaluation of cryoablation using a prototype cryoablation needle in swine liver.Clinical endoscopy · 2024Article
- Tissue Ablation: Applications and Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Review
- Prospect of Gold Nanoparticles in Pancreatic Cancer.Pharmaceutics · 2024Review
- Intraoperative radiofrequency ablation for unresectable abdominal paraganglioma: a case report.Frontiers in endocrinology · 2024Article
- Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation.Exploration of targeted anti-tumor therapy · 2024Review
- Review
- Advancements in Microwave Ablation Techniques for Managing Pancreatic Lesions.Life (Basel, Switzerland) · 2023Review
- Mechanisms and therapeutic strategies to combat the recurrence and progression of hepatocellular carcinoma after thermal ablation.Journal of interventional medicine · 2023Article
- Locoregional Therapies and Remodeling of Tumor Microenvironment in Pancreatic Cancer.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most aggressive malignancies of the digestive tract and carries a poor prognosis. The majority of patients have advanced disease at the time of diagnosis. Surgical resection offers the only curative treatment, but only a small proportion of patients can undergo surgical resection. Radiofrequency ablation (RFA) is a well-known modality in the management of solid organ tumors, however, its utility in the management of pancreatic cancer is under investigation. Since the past decade, there is increasing use of RFA as it provides a feasible palliation treatment in the management of unresectable pancreatic cancer. RFA causes tumor cytoreduction through multiple mechanisms such as coagulative necrosis, protein denaturation, and activation of anticancer immunity. The safety profile of RFA is controversial because of the high risk for complications, however, small prospective and retrospective studies have shown promising results in its applicability for palliative management of unresectable pancreatic malignancies. In this review, we discuss different approaches of RFA, their indications, technical accessibility, safety, and major complications in the management of unresectable pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.